Navigation Links
Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/3/2008

- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly -

SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of its third cohort of patients in a Phase 1 clinical trial of new HspE7 (HspE7 + Poly-ICLC) in patients with cervical intraepithelial neoplasia (CIN). The safety data from the cohort were normal and met the limits prescribed in the trial protocol, allowing advancement to the fourth cohort of patients in the study.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

The evaluation by the Safety Review Committee was performed after the third cohort reached five weeks of treatment (two doses plus one week of follow-up). The dosing of the fourth cohort of patients is expected shortly.

At the end of each cohort, Nventa is also collecting immunological data that may provide an early indication of potential efficacy of the compound. All patients are being typed for class I and II human leukocyte antigen (HLA) subtypes, and are being evaluated for cytokine responses, anti-HspE7 antibodies and cellular (T-cell) immunology.

The trial is expected to dose up to 5 cohorts comprising twenty-four patients. The first cohort of patients was administered 500 mcg of HspE7 and 50 mcg of adjuvant containing Poly-IC, a toll-like receptor-3 (or TLR3) agonist. The second cohort was administered 500 mcg of HspE7 and an escalated dose of 500 mcg of adjuvant. The third cohort was administered 500 mcg of HspE7 and 1,000 mcg of adjuvant. The fourth cohort will be administered 500 mcg of HspE7 and 2,000 mcg of adjuvant. An additional cohort of patients administered 1,000 mcg of HspE7 and 2,000 mcg of adjuvant may be added if deemed appropriate based on data from the previous four cohorts.

Following successful completion of th
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014   Royal Philips (NYSE: ... has received 510(k) clearance from the U.S. Food ... application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through ... with pre-procedural, high-precision positioning to treat aortic stenosis ... is available as part of Philips IntelliSpace ...
(Date:8/21/2014)... CYBX ) today announced results for the quarter ...   Operating results for the first quarter of ... and other achievements, include: , Worldwide net product sales ... international net sales of $13.2 million, an increase of 14.5% ... sales reached a new high of $58.8 million, an increase ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
(Date:8/21/2014)... DMG Productions announces the upcoming airing of Innovations ... August 25, 2014 at 7:00 a.m. EST and 7:00 ... episode, Innovations will go behind-the-scenes to demonstrate how Freenotes ... Audiences will be amazed by the park's that focus ... providing access to real musical instruments. , Audiences will ...
(Date:8/21/2014)... August 21, 2014 Being overweight or ... painful osteoarthritis. Although there is no cure, patients have ... making certain lifestyle changes, such as losing excess weight ... , Osteoarthritis is a joint disorder which causes discomfort ... and neck and can significantly reduce one’s quality of ...
(Date:8/21/2014)... Australian scientists say a commercially available compound ... used to successfully fight mesothelioma in lab mice. Surviving ... research. Click here to read it now. ... mesothelioma cells with the S. aureus mixture ... simultaneously stimulating a stronger anti-tumor response in healthy cells. ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... wellness in all aspects of life, St. Louis’ Sound ... for the better and revolutionized its online presence. Reorganized ... Mind Café, the new website makes navigating for information ... blue and an easily accessible menu-bar in jet black, ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Bunion Bootie ... Pedorthics, a bi-monthly publication of the Pedorthic Footcare Association and ... , Bunion Bootie is a new ... for bunion sufferers and their pain. It is extremely comfortable ... any shoe to eliminate the friction and rubbing of shoes ...
Breaking Medicine News(10 mins):Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:Diet Doc’s Medical Weight Loss Programs Announces Safe and Fast Weight Loss That Teach Patients How to Relieve Osteoarthritis Pain 2Health News:Diet Doc’s Medical Weight Loss Programs Announces Safe and Fast Weight Loss That Teach Patients How to Relieve Osteoarthritis Pain 3Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:Sound Mind Cafe Launches Revamped Website and Hires Hypnotist to Team 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3
... China is implementing family planning policies is often held ... ,Well the element of coercion may be ... exploding beyond relentlessly.,The riots against punitive measures reported last ... being done over there.,Worse, the Chinese citizens are virtually ...
... stents in the treatment of coronary artery blockage is common ... patients receiving drug-coated stents for off-label indications, according to ... ,Stents are tiny mesh tubes used to prop open ... obstructed coronary artery. The newer drug-eluting stents are normal metal ...
... of tuberculosis in Britain, senior doctors here want all ... the disease. ,The doctors want the ... ,The Observer reported Sunday that two new outbreaks, in ... officials were failing to come to grips with the ...
... Researchers studying the genetics behind why C. difficile causes disease ... it because they are starving. That just might help them ... a very difficult disease to treat. ,"The genes ... periods of nutrient deprivation. This is consistent with the view ...
... person dies of it every 30 seconds, it rivals HIV ... vast majority of its victims are under five years old. ... Ross was awarded the Nobel Prize for finally proving that ... Nottingham believe they have made a significant breakthrough in the ...
... Commissioner for Human Rights: 'Universal access to health care is not ... cannot implement that human right without effective health systems. We ... this simple message stick.' ,The International Day ... year. ,The origins of this world health day ...
Cached Medicine News:Health News:Chinese Take Fertility Drugs to Beat One Child Policy 2Health News:Chinese Take Fertility Drugs to Beat One Child Policy 3Health News:Off-label and Untested Use of Drug-coated Stents Appears Widespread 2Health News:Understanding Why C. Difficile Causes Disease -- It's Hungry 2Health News:Vaccine Hope for Malaria 2Health News:International Day Of Action For Women's Health - 2007 2Health News:International Day Of Action For Women's Health - 2007 3Health News:International Day Of Action For Women's Health - 2007 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: